Questcor Pharmaceuticals (QCOR) acquires the rights to develop the autoimmune drug Synacthen in...

|By:, SA News Editor

Questcor Pharmaceuticals (QCOR) acquires the rights to develop the autoimmune drug Synacthen in the U.S. from Novartis (NVS) for an upfront payment of $60M. Additional payments of $75M plus certain milestone and royalty payments are expected going forward. QCOR shares +9.9% premarket, NVS is off 0.76%. (PR)